Psoriasis image, androgenetic alopecia studies among week's top five dermatology reads

Study results of an image-based survey that found images of psoriasis to be as bothersome as those of herpes labialis was among the most-read article of the past week on Healio.com/Dermatology.

Other widely read articles included study results on the use of Xeljanz as potential vitiligo treatment and the initiation of a trial of an over-the-counter wearable hair restoration device in men with androgenetic alopecia:

Psoriasis, herpes labialis highly stigmatizing, image-based survey reports

Participants of an image-based survey found images of psoriasis to be as bothersome as those of herpes labialis in some categories, according to recently published study results.

Researchers used an image-based questionnaire to study and compare the public’s attitude towardpsoriasis, to identify factors that contribute to its stigmatization and to compare perceptions of psoriasis against other common dermatological conditions including atopic dermatitis, acne, vitiligo, rosacea, herpes labialis, warts and tinea versicolor. Read more

Xeljanz might be effective as vitiligo treatment

Xeljanz was effective as treatment in a patient with vitiligo, according to recently published study results.

“While it’s one case, we anticipated the successful treatment of this patient based on our current understanding of the disease and how the drug works,” researcher Brett A. King, MD, PhD, assistant professor of dermatology, Yale University School of Medicine, said in a press release. Read more

Can-Fite provides update on psoriasis, RA studies, reports financial results

Can-Fite BioPharma Ltd. reported financial results for 6 months ending June 30 and gave updates on data from its studies on patients with moderate-to-severe psoriasis and rheumatoid arthritis.

Can-Fite announced it is preparing the protocol for another advanced psoriasis trial based on positive data from its completed phase 2/3 study suggesting CF101 was a potential systematic therapy for patients with moderate-to-severe psoriasis, according to the release. Read more

Hair restoration study begun in men with androgenetic alopecia

Theradome announced in a press release it has begun recruiting men with androgenetic alopecia in a 26-week clinical trial of its over-the-counter wearable hair restoration device that uses targeted laser energy.

The Theradome LH80 PRO Laser Helmet is FDA-cleared for women, according to the release. Ken Washenik, MD, PhD, a clinical researcher in hair loss, will oversee the study, according to the release. Read more

FDA grants orphan drug status to Humira for treatment of hidradenitis suppurativa

AbbVie announced today that the FDA has granted orphan drug designation to Humira for treating moderate-to-severe hidradenitis suppurativa.

The supplemental biologic license application by Abbvie seeking the agency’s approval for the use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease) is being reviewed by the FDA, according to a press release. Read more